Spots Global Cancer Trial Database for IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: IMA401 TCER® in Recurrent and/or Refractory Solid Tumors
Official Title: A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors.
Study ID: NCT05359445
Study Description
Brief Summary: Primary objective: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 Secondary objectives: * To characterize the safety and tolerability of IMA401 * To evaluate initial anti-tumor activity of IMA401 * To describe the pharmacokinetics of IMA401
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I, Freiburg, Baden-Wurttemberg, Germany
Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten, Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen, Tuebingen, Baden-Wurttemberg, Germany
Universitaetsklinikum Ulm AöR, ECTU-Early clinical Trials Unit Universitaetsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU, Ulm, Baden-Wurttemberg, Germany
Universitaetsklinikum Erlangen AöR, Interdisciplinary Clinical Trial Unit with ECTU, Erlangen, Bavaria, Germany
Klinikum rechts der Isar der TU Muenchen AöR, Klinik und Poliklinik fuer Innere Medizin III, Munich, Bavaria, Germany
Klinikum Nuernberg, Klinik fuer Innere Medizin 5, Abteilung Onkologie/Haematologie, Nuremberg, Bavaria, Germany
Universitaetsklinikum Regensburg AöR, Klinik fuer Innere Medizin 3, Regensburg, Bavaria, Germany
Universitaetsklinikum Wuerzburg AöR, Interdisziplinaeres Studienzentrum mit ECTU, Wuerzburg, Bavaria, Germany
Medizinische Hochschule Hannover, Klinik fuer Haematologie, Haemostaseologie, Onkologie und Stammzelltransplantation, Hanover, Lower Saxony, Germany
Universitätsklinikum Bonn AöR, Medizinische Klinik IIII, Bonn, North Rhine-Westphalia, Germany
Marien Hospital Duesseldorf GmbH, Klinik fuer Onkologie/Haematologie und Palliativmedizin, Duesseldorf, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen AöR, Innere Klinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Muenster AöR, Medizinische Klinik A, Muenster, North Rhine-Westphalia, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, III. Medizinische Klinik, Mainz, Rhineland-Palatinate, Germany
Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Chemnitz, Saxony, Germany
Universitaetsklinikum C. - G. - Carus Dresden, Technische Universitaet Dresden AöR, NCT/UCC Early Clinical Trial Unit, Dresden, Saxony, Germany
Universitaet Leipzig, Universitaeres Krebszentrum Leipzig (UCCL), Leipzig, Saxony, Germany
Universitaetsklinikum Schleswig- Holstein, Campus Kiel, Medizinische Klinik II Haematologie und Onkologie, Karl-Lennert Tumorzentrum, Kiel, Schleswig- Holstein, Germany
Charité Universitaetsmedizin Berlin KöR, Klinik fuer Haematologie und Onkologie, Berlin, , Germany
Contact Details
Name: Immatics Biotechnologies GmbH
Affiliation: Immatics Biotechnologies GmbH
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
